bay1125976
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2013 (NCT01915576)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase AKT2INHIBITOR
AKT2 inhibitor
Allosteric inhibitor.
- Serine/threonine-protein kinase AKTINHIBITOR
AKT1 inhibitor
Allosteric inhibitor.
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1- Mol. weight
- 383.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4751394 ↗
- ChEMBLCHEMBL3545049 ↗
Also known as
- bay1125976
- bay1125976
- bay-1125976
- bay-1125976
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01915576 | Phase 1 | Sep 1, 2013 | Bayer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 1 | 1 | 1 | 2013 |
1 organizations
Page 1 / 1